Coronavirus Live Count Map India
remove_red_eye 578 Views
COVID-19 Vaccine Updates
Sustaining a Healthy Heart against Trans Fatty Acid (TFA)
By Dr Sundeep Mishra
Even as the ongoing pandemic takes a toll on the health and well-being of the world, the other silent epidemic of non-communicable diseases (NCDs) including cardio-vascular diseases, stroke, cancer, and diabetes continue to kill 41 million people annually. Cardiovascular account for nearly half of all NCD deaths and many of these deaths are in people under 70 years of age, and most occur in low- and middle-income countries. Research has revealed that consumption of high levels of trans fatty acids (TFA) increases the risk of coronary heart disease and death. World over, approximately half a million people die of CHD that can be directly linked to TFA consumption. In India, this number is at least as high as 72,000 people annually. WHO has called for elimination of TFA from the global food supply by 2023.It is considered a health best buy – a policy measure that will positively impact several million lives. In the last few decades, India has witnessed a significant rapid change in dietary patterns that has led to the rise of NCDs and related comorbidities in young children, adolescents, young adults....read more
Dyslipidemia: Whats new in "the lower, the better"
Prevention is always better than cure. Join us today on Medtalks with Dr KK Aggarwal COVID edition at 7:00 pm as we discuss dyslipidemia, which is a well-established risk factor for cardiovascular diseases. Just click on www.facebook.com/drkkaggarwal or https://perfecthealthmela.com/vevent/general-webinar.php
Healthcare News Monitor
The four southern states of Karnataka, Tamil Nadu, Goa, and Kerala in India are achieving very different success levels in pharma manufacturing, despite their proximity: Karnataka is a major biologics player and the tiny state of Goa has an outsized manufacturing industry, while Kerala and Tamil Nadu lag behind. Karnataka has one of the fastest-growing pharmaceutical sectors in India: approximately 40% of the state’s pharma production is exported overseas. The state is an emerging pharma powerhouse, particularly its city of Bangalore, and its success is largely driven by its biologics production. A former Portuguese colony, Goa is geographically tiny but its pharma industry is overrepresented and has ties to European companies. Kerala is a much larger state but has a very underrepresented pharma industry, partly due to a left-wing government not being able to attract businesses. Tamil Nadu has a solid pharma industry but is not as attractive to international pharma companies and innovative companies as its neighbour Karnataka.
Centaur Pharmaceuticals is launching a diabetic foot ulcer treatment drug Woxheal, a New Chemical Entity (NCE) in the country. The product will be made available from October 1, 2020, across the country. The drug will cost Rs 1850 for a week’s treatment. The company will be manufacturing the medication from its facilities located in Mumbai and Goa and the active pharmaceutical ingredients (APIs) from its site located in Pune. All the three facilities are US FDA approved. S D Sawant, Chairman and MD, Centaur Pharmaceuticals said, “It is a unique product for the treatment of diabetic foot ulcers, and we are sure that it will save millions of diabetics who have to undergo foot amputation globally. This is a result of intense research work which have been carried in the last 14 years for developing this novel drug.”
NEW DELHI : Joginder Chaudhary was his parents’ greatest pride, raised with the little they earned farming a half-acre plot in central India to become the first doctor from their village. For the coronavirus, though, he was just one more in a million. After the virus killed the 27-year-old Chaudhary in late July, his mother wept inconsolably. With her son gone, Premlata Chaudhary said, how could she go on living? Three weeks later, on Aug. 18, the virus took her life, too — yet another number in an unrelenting march toward a woeful milestone.
The Indian Express
GOVERNMENT doctors from Yavatmal on Monday organised a protest against alleged “ill-treatment” by the district collector and Revenue department officials at tahsil level, and put forward a charter of demands. A delegation of the Maharashtra State Gazetted Health Officers’ Organisation met Collector M D Singh and handed over a memorandum of demands to him. The letter claimed that the Collector had “ill treated” District Health Officer Vijay Chavan, who had gone on leave. “The Collector and other revenue officials used unofficial language and give uncivilised treatment to the DHO and other government health officials. They have threatened them with action under the Epidemic Diseases Act, leading to their demoralisation,” read the letter.